Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27774912,globule,"The optimized formulation has globule size- 187.6 nm, zeta potential- -9.81 mv, viscosity- 1.772 cps and infinite dilution ability.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),nm,187.6,10869,DB05812,Abiraterone
,27774912,zeta potential,"The optimized formulation has globule size- 187.6 nm, zeta potential- -9.81 mv, viscosity- 1.772 cps and infinite dilution ability.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),mv,9.81,10870,DB05812,Abiraterone
,27774912,viscosity,"The optimized formulation has globule size- 187.6 nm, zeta potential- -9.81 mv, viscosity- 1.772 cps and infinite dilution ability.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),cps,1.772,10871,DB05812,Abiraterone
,27774912,drug release,In vitro drug release was 98.21% and was found to be significantly different from the marketed product and plain drug.,Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),%,98.21,10872,DB05812,Abiraterone
,27774912,"Cmax, AUC0t","The Cmax, AUC0t of naproxen was boosted with SEDDS to 133.63 g/ml and 698.29 hr.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),[g] / [ml],133.63,10873,DB05812,Abiraterone
,27774912,"Cmax, AUC0t","The Cmax, AUC0t of naproxen was boosted with SEDDS to 133.63 g/ml and 698.29 hr.",Development of Self Emulsifying Formulations of Poorly Soluble Naproxen for Enhanced Drug Delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27774912/),h,698.29,10874,DB05812,Abiraterone
,26096139,area under plasma concentration-time curve (AUC),"In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1942,35842,DB05812,Abiraterone
,26096139,area under plasma concentration-time curve (AUC),"In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],4077,35843,DB05812,Abiraterone
,26096139,area under plasma concentration-time curve (AUC),"In healthy subjects, geometric mean (GM) abiraterone area under plasma concentration-time curve (AUC) increased ∼5- and ∼10-fold, respectively, with low-fat and high-fat meals versus fasted state (GM [coefficient of variation], 1942 [48] and 4077 [37] ng · h/mL vs 421 [67] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],421,35844,DB05812,Abiraterone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1992,35845,DB05812,Abiraterone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],973,35846,DB05812,Abiraterone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1264,35847,DB05812,Abiraterone
,26096139,AUC,"In mCRPC patients, abiraterone AUC was ∼2-fold higher with a high-fat meal and similar with a low-fat meal versus modified fasting state (GM [coefficient of variation]: 1992 [34] vs 973 [58] ng · h/mL and 1264 [65] vs 1185 [90] ng · h/mL, respectively).",Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26096139/),[h·ng] / [ml],1185,35848,DB05812,Abiraterone
,30671920,maximum plasma concentration (Cmax),"The pharmacokinetic results for abiraterone acetate showed a mean for the maximum plasma concentration (Cmax) of 54.67 ± 68.30 pg/ml, and a median time to maximum concentrations (tmax) of 5.53 h (range 2.67-35.00 h).",Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671920/),[pg] / [ml],54.67,60963,DB05812,Abiraterone
,30671920,time to maximum concentrations (tmax),"The pharmacokinetic results for abiraterone acetate showed a mean for the maximum plasma concentration (Cmax) of 54.67 ± 68.30 pg/ml, and a median time to maximum concentrations (tmax) of 5.53 h (range 2.67-35.00 h).",Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671920/),h,5.53,60964,DB05812,Abiraterone
,30671920,area under the concentration-time curve (AUC) from time 0 h to infinity (AUCinf),"The means for area under the concentration-time curve (AUC) from time 0 h to infinity (AUCinf) and AUC from time zero h to the time of the last measurable abiraterone acetate concentrations (AUCt) were 386.13 ± 266.80 pg·h/ml and 460.07 ± 378.78 pg·h/ml, respectively.",Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671920/),[h·pg] / [ml],386.13,60965,DB05812,Abiraterone
,30671920,AUC from time zero h to the time of the last measurable abiraterone acetate concentrations (AUCt),"The means for area under the concentration-time curve (AUC) from time 0 h to infinity (AUCinf) and AUC from time zero h to the time of the last measurable abiraterone acetate concentrations (AUCt) were 386.13 ± 266.80 pg·h/ml and 460.07 ± 378.78 pg·h/ml, respectively.",Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671920/),[h·pg] / [ml],460.07,60966,DB05812,Abiraterone
,30671920,apparent elimination half-life (t1/2),The apparent elimination half-life (t1/2) showed a mean of 8.98 ± 3.92 h.,Evaluation of the Pharmacokinetics of Abiraterone Acetate and Abiraterone Following Single-Dose Administration of Abiraterone Acetate to Healthy Subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671920/),h,8.98,60967,DB05812,Abiraterone
,22763809,flow rate,"The chromatographic analysis was performed on a Waters Alliance system with a Betasil C(18) column maintained at ambient room temperature and an isocratic mobile phase [acetonitrile-water-10 mm potassium dihydrogen phosphate (pH 3.0), 55:5:40, v/v/v] at a flow rate of 1.00 mL/min with a total run time of 10 min.",Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763809/),[ml] / [min],1.00,63304,DB05812,Abiraterone
,22763809,total run time,"The chromatographic analysis was performed on a Waters Alliance system with a Betasil C(18) column maintained at ambient room temperature and an isocratic mobile phase [acetonitrile-water-10 mm potassium dihydrogen phosphate (pH 3.0), 55:5:40, v/v/v] at a flow rate of 1.00 mL/min with a total run time of 10 min.",Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763809/),min,10,63305,DB05812,Abiraterone
,23020788,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) of abiraterone was 10.4 ng/mL, mean area under the plasma concentration-time curve (AUC) from 0 to the last measurable plasma concentration (AUC0-last) was 74.8 ng·h/mL.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),[ng] / [ml],10.4,74881,DB05812,Abiraterone
,23020788,area under the plasma concentration-time curve (AUC) from 0 to the last measurable plasma concentration (AUC0-last),"The mean maximum plasma concentration (Cmax) of abiraterone was 10.4 ng/mL, mean area under the plasma concentration-time curve (AUC) from 0 to the last measurable plasma concentration (AUC0-last) was 74.8 ng·h/mL.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),[h·ng] / [ml],74.8,74882,DB05812,Abiraterone
,23020788,Cmax,"The exposures for TR in plasma (Cmax = 3429 ng·eq/mL; AUC0-last = 26,683 ng eq·h/mL) and whole blood (Cmax = 1836 ng·eq/mL; AUC0-last = 12,162 ng·eq·h/mL) were >300-fold higher than abiraterone exposure in plasma.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),[eq·ng] / [ml],3429,74883,DB05812,Abiraterone
,23020788,AUC0-last,"The exposures for TR in plasma (Cmax = 3429 ng·eq/mL; AUC0-last = 26,683 ng eq·h/mL) and whole blood (Cmax = 1836 ng·eq/mL; AUC0-last = 12,162 ng·eq·h/mL) were >300-fold higher than abiraterone exposure in plasma.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),[eq·h·ng] / [ml],"26,683",74884,DB05812,Abiraterone
,23020788,Cmax,"The exposures for TR in plasma (Cmax = 3429 ng·eq/mL; AUC0-last = 26,683 ng eq·h/mL) and whole blood (Cmax = 1836 ng·eq/mL; AUC0-last = 12,162 ng·eq·h/mL) were >300-fold higher than abiraterone exposure in plasma.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),[eq·ng] / [ml],1836,74885,DB05812,Abiraterone
,23020788,AUC0-last,"The exposures for TR in plasma (Cmax = 3429 ng·eq/mL; AUC0-last = 26,683 ng eq·h/mL) and whole blood (Cmax = 1836 ng·eq/mL; AUC0-last = 12,162 ng·eq·h/mL) were >300-fold higher than abiraterone exposure in plasma.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),[eq·h·ng] / [ml],"12,162",74886,DB05812,Abiraterone
,23020788,recovery,"Mean recovery of TR in faeces was 87.9%, indicating faeces as primary route of excretion.","A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23020788/),%,87.9,74887,DB05812,Abiraterone
,18674917,IC(50),"Another rather potent and more selective inhibitor (compound 23, IC(50)=345 nM) was further examined in rats regarding plasma testosterone levels and pharmacokinetic properties.","Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674917/),nM,345,78974,DB05812,Abiraterone
,18674917,plasma half-life,"Compared to the reference Abiraterone, 23 was more active in vivo, showed a longer plasma half-life (10h) and a higher bioavailability.","Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18674917/),h,10,78975,DB05812,Abiraterone
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,22.8,104479,DB05812,Abiraterone
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,36.8,104480,DB05812,Abiraterone
,20399458,overall survival,"Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001).",A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),month,10.3,104481,DB05812,Abiraterone
,20399458,maximum tolerated dose,Combination regimens using 600 mg ketoconazole daily were fairly well tolerated and the maximum tolerated dose of docetaxel was 32 mg/m(2).,A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20399458/),mg,32,104482,DB05812,Abiraterone
,34256892,half-life (T1/2),"Results: The half-life (T1/2) values of lipid-based formulation (LBF) abiraterone acetate tablet samples (75 mg/tablet) and reference tablets (250 mg/tablet) after oral administration were 3.42 and 4.27 h, respectively, while the area under the concentration time curve (AUC0-t) (h·ng/mL) values were 107.71 and 52.83, respectively.",Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256892/),h,3.42,108622,DB05812,Abiraterone
,34256892,half-life (T1/2),"Results: The half-life (T1/2) values of lipid-based formulation (LBF) abiraterone acetate tablet samples (75 mg/tablet) and reference tablets (250 mg/tablet) after oral administration were 3.42 and 4.27 h, respectively, while the area under the concentration time curve (AUC0-t) (h·ng/mL) values were 107.71 and 52.83, respectively.",Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256892/),h,4.27,108623,DB05812,Abiraterone
,34256892,area under the concentration time curve (AUC0-t),"Results: The half-life (T1/2) values of lipid-based formulation (LBF) abiraterone acetate tablet samples (75 mg/tablet) and reference tablets (250 mg/tablet) after oral administration were 3.42 and 4.27 h, respectively, while the area under the concentration time curve (AUC0-t) (h·ng/mL) values were 107.71 and 52.83, respectively.",Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256892/),[h·ng] / [ml],107.71,108624,DB05812,Abiraterone
,34256892,area under the concentration time curve (AUC0-t),"Results: The half-life (T1/2) values of lipid-based formulation (LBF) abiraterone acetate tablet samples (75 mg/tablet) and reference tablets (250 mg/tablet) after oral administration were 3.42 and 4.27 h, respectively, while the area under the concentration time curve (AUC0-t) (h·ng/mL) values were 107.71 and 52.83, respectively.",Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256892/),[h·ng] / [ml],52.83,108625,DB05812,Abiraterone
,34256892,relative bioavailability,The F value of the relative bioavailability was 704.80%.,Pharmacokinetics of abiraterone acetate released from a tablet based on lipid matrix in beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34256892/),%,704.80,108626,DB05812,Abiraterone
,18061460,IC50,"Two potent inhibitors (27, IC50 = 373 nM/28, IC50 = 953 nM) were further examined in rats regarding their effects on plasma testosterone levels and their pharmacokinetic properties.","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),nM,373,118459,DB05812,Abiraterone
,18061460,IC50,"Two potent inhibitors (27, IC50 = 373 nM/28, IC50 = 953 nM) were further examined in rats regarding their effects on plasma testosterone levels and their pharmacokinetic properties.","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),nM,953,118460,DB05812,Abiraterone
,18061460,"bioavailability,","Compound 28 was similarly active as abiraterone and showed better pharmacokinetic properties (higher bioavailability, t(1/2) 9.5 h vs 1.6 h).","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),h,9.5,118461,DB05812,Abiraterone
,18061460,t(1/2),"Compound 28 was similarly active as abiraterone and showed better pharmacokinetic properties (higher bioavailability, t(1/2) 9.5 h vs 1.6 h).","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),h,9.5,118462,DB05812,Abiraterone
,18061460,t(1/2),"Compound 28 was similarly active as abiraterone and showed better pharmacokinetic properties (higher bioavailability, t(1/2) 9.5 h vs 1.6 h).","Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061460/),h,1.6,118463,DB05812,Abiraterone
,29856824,maximum plasma concentration,The maximum plasma concentration ranged from 35.7 to 182 ng/mL and was not consistently above the minimum effective concentration in preclinical studies.,A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29856824/),[ng] / [ml],35.7 to 182,124238,DB05812,Abiraterone
,28776077,t max,The novel formulation of AA allows rapid absorption of the compound with t max values within 1 hour.,Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28776077/),h,1,127486,DB05812,Abiraterone
,30279580,plasma concentration,"For enzalutamide, no significant differences in exposure were found, except for carboxylic acid enzalutamide, having a median plasma concentration of 5.8 mg/L versus 3.9 mg/L in the oldest versus the youngest age quartile (CV 66%, p = 0.03).",Impact of age on exposure to oral antiandrogen therapies in clinical practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30279580/),[mg] / [l],5.8,133616,DB05812,Abiraterone
,30279580,plasma concentration,"For enzalutamide, no significant differences in exposure were found, except for carboxylic acid enzalutamide, having a median plasma concentration of 5.8 mg/L versus 3.9 mg/L in the oldest versus the youngest age quartile (CV 66%, p = 0.03).",Impact of age on exposure to oral antiandrogen therapies in clinical practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30279580/),[mg] / [l],3.9,133617,DB05812,Abiraterone
,30610953,tmax,"One surprising finding, however, was the very rapid absorption observed both in dogs and in humans with median tmax values in the 0.5-0.75 h range.",Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610953/),h,0.5-0.75,142539,DB05812,Abiraterone
,29150561,AUC0-24h,"The geometric mean AUC0-24h of cabazitaxel was 181 ng*h/mL (95% CI, 150-219 ng*h/mL) in cycle 3 and 234 ng*h/mL (95% CI, 209-261 ng*h/mL) in cycle 1.",Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29150561/),[h·ng] / [ml],181,144767,DB05812,Abiraterone
,29150561,AUC0-24h,"The geometric mean AUC0-24h of cabazitaxel was 181 ng*h/mL (95% CI, 150-219 ng*h/mL) in cycle 3 and 234 ng*h/mL (95% CI, 209-261 ng*h/mL) in cycle 1.",Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29150561/),[h·ng] / [ml],234,144768,DB05812,Abiraterone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,1.3-3.0,151300,DB05812,Abiraterone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,1.6-2.9,151301,DB05812,Abiraterone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,0.044-0.15,151302,DB05812,Abiraterone
,27504016,IC50,"Abiraterone acetate and abiraterone and its major metabolites, abiraterone sulfate and abiraterone sulfate N-oxide, inhibited CYP2C8 in human liver microsomes, with IC50 values near or below the peak total concentrations observed in patients with metastatic castration-resistant prostate cancer (IC50 values: 1.3-3.0 µM, 1.6-2.9 µM, 0.044-0.15 µM, and 5.4-5.9 µM, respectively).","In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27504016/),μM,5.4-5.9,151303,DB05812,Abiraterone
,25204404,apparent clearance,"Abiraterone pharmacokinetics were characterized by an extensive apparent clearance, which was lower in patients with mCRPC (1,550 L/h) versus healthy subjects (2,240 L/h), and by large apparent central (5,620 L) and peripheral (17,400 L) volumes of distribution.",Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25204404/),[l] / [h],"1,550",160270,DB05812,Abiraterone
,25204404,apparent clearance,"Abiraterone pharmacokinetics were characterized by an extensive apparent clearance, which was lower in patients with mCRPC (1,550 L/h) versus healthy subjects (2,240 L/h), and by large apparent central (5,620 L) and peripheral (17,400 L) volumes of distribution.",Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25204404/),[l] / [h],"2,240",160271,DB05812,Abiraterone
,25204404,apparent central,"Abiraterone pharmacokinetics were characterized by an extensive apparent clearance, which was lower in patients with mCRPC (1,550 L/h) versus healthy subjects (2,240 L/h), and by large apparent central (5,620 L) and peripheral (17,400 L) volumes of distribution.",Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25204404/),l,"5,620",160272,DB05812,Abiraterone
,25204404,apparent central,"Abiraterone pharmacokinetics were characterized by an extensive apparent clearance, which was lower in patients with mCRPC (1,550 L/h) versus healthy subjects (2,240 L/h), and by large apparent central (5,620 L) and peripheral (17,400 L) volumes of distribution.",Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25204404/),l,"17,400",160273,DB05812,Abiraterone
,25204404,peripheral,"Abiraterone pharmacokinetics were characterized by an extensive apparent clearance, which was lower in patients with mCRPC (1,550 L/h) versus healthy subjects (2,240 L/h), and by large apparent central (5,620 L) and peripheral (17,400 L) volumes of distribution.",Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25204404/),l,"17,400",160274,DB05812,Abiraterone
,33795255,MAD,The MTD was not identified; the MAD was 0.3 mg/kg.,"Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33795255/),[mg] / [kg],0.3,161602,DB05812,Abiraterone
,33795255,half-life,MEDI3726 had nonlinear pharmacokinetics with a short half-life (0.3-1.8 days).,"Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33795255/),d,0.3-1.8,161603,DB05812,Abiraterone
<,32278053,oral bioavailability,Abiraterone acetate (AbA) has an oral bioavailability of <10% due to its poor water solubility.,Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32278053/),%,10,169836,DB05812,Abiraterone
,32278053,saturation levels,"SLH with a saturation level of 90% Seq enhanced the oral bioavailability of unformulated AbA by 31-fold, and super-SLH with saturation levels of 150, 200 and 250% Seq, enhanced the bioavailability by 11, 10 and 7-fold, respectively.",Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32278053/),,150,169837,DB05812,Abiraterone
,28039155,progression-free survival,Median PSA-progression-free survival was 6.9 months (95% CI: 4.1-10.3 months).,Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039155/),month,6.9,200333,DB05812,Abiraterone
,22002259,flow-rate,"Chromatographic separation was achieved using an isocratic mobile (10 mm ammonium acetate:acetonitrile, 10:90, v/v) at a flow-rate of 0.70 mL/min on an Atlantis dC(18) column maintained at 40 °C with a total run time of 3.5 min.",Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22002259/),[ml] / [min],0.70,217729,DB05812,Abiraterone
,22002259,total run time,"Chromatographic separation was achieved using an isocratic mobile (10 mm ammonium acetate:acetonitrile, 10:90, v/v) at a flow-rate of 0.70 mL/min on an Atlantis dC(18) column maintained at 40 °C with a total run time of 3.5 min.",Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22002259/),min,3.5,217730,DB05812,Abiraterone
≥,32172196,minimum plasma concentration (Cmin),"At the currently used fixed dose of 1000 mg once daily in modified fasting state, 40% of patients do not reach the efficacy threshold of a minimum plasma concentration (Cmin) ≥ 8.4 ng/mL and are thereby at risk of decreased treatment efficacy.",Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32172196/),[ng] / [ml],8.4,218086,DB05812,Abiraterone
<,32172196,Cmin,"In case of Cmin < 8.4 ng/mL and acceptable toxicity, a PK-guided intervention was recommended.",Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32172196/),[ng] / [ml],8.4,218087,DB05812,Abiraterone
<,32172196,Cmin,"In total, 32 evaluable patients were included, of which 20 patients (63%) had a Cmin < 8.4 ng/mL at a certain time point during treatment.",Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32172196/),[ng] / [ml],8.4,218088,DB05812,Abiraterone
,32172196,Cmin,"These patients were recommended to take abiraterone acetate concomitantly with food, after which Cmin increased from 6.9 ng/mL to 27 ng/mL (p < 0.001) without additional toxicities.",Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32172196/),[ng] / [ml],6.9,218089,DB05812,Abiraterone
,32172196,Cmin,"These patients were recommended to take abiraterone acetate concomitantly with food, after which Cmin increased from 6.9 ng/mL to 27 ng/mL (p < 0.001) without additional toxicities.",Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32172196/),[ng] / [ml],27,218090,DB05812,Abiraterone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,58,227698,DB05812,Abiraterone
,29590007,response rate,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),%,50,227699,DB05812,Abiraterone
,29590007,PFS,"The PSA response rate was 58% in LOW and 50% in STD, and the median PFS was approximately 9 months in both groups.",Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29590007/),month,9,227700,DB05812,Abiraterone
,31081533,DTL,"Considerable inter-patient variability in DTL was seen, with initial DTL for abiraterone ranging between 1.5 and 25.4 ng/ml (CV 61%) and for D4A between 0.2 and 2.5 ng/ml (CV 61%).",Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31081533/),ng,1,229856,DB05812,Abiraterone
,33709626,area under the plasma concentration-time curve (mAUC0-inf),The mean docetaxel area under the plasma concentration-time curve (mAUC0-inf) was 461 ng/mL × h with 1 dose limiting toxicity (DLT); grade 3 alanine transferase increase.,"ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],461,232532,DB05812,Abiraterone
,33709626,mAUC0-inf,"In cohort 2 (n = 6, ModraDoc006/r 30-20/200-200), the mAUC0-inf was 1687 ng/mL × h with 2 DLTs; grade 3 diarrhea and mucositis.","ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],1687,232533,DB05812,Abiraterone
,33709626,mAUC0-inf,"In cohort 3A (n = 6, ModraDoc006/r 30-20/200-100), the mAUC0-inf was 1517 ng/mL × h with 1 DLT; grade 3 diarrhea.","ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],1517,232534,DB05812,Abiraterone
,33709626,mAUC0-inf,"In cohort 3B (n = 3, ModraDoc006/r 20-20/200-100), the mAUC0-inf was 558 ng/mL × h without DLTs.","ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33709626/),[ng] / [h·ml],558,232535,DB05812,Abiraterone
,29974203,ΔQTcF,"At steady state, the maximum ΔQTcF was 12.4 ms and the upper bound of its associated 90% CI was 16.0 ms.","An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29974203/),ms,12.4,235962,DB05812,Abiraterone
,29974203,ΔQTcF,"At steady state, the maximum ΔQTcF was 12.4 ms and the upper bound of its associated 90% CI was 16.0 ms.","An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29974203/),ms,16.0,235963,DB05812,Abiraterone
,25117615,tmax,"Over the evaluated dose range, plasma abiraterone concentrations increased with dose, with median tmax 2-3 h.",Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25117615/),h,2-3,262377,DB05812,Abiraterone
,26006702,plasma t1/2,Onapristone plasma t1/2 (mean ± SD) was 4.36 ± 0.81 h for the fasted state and 3.76 ± 0.36 h for the fed state.,A single-dose PK study of onapristone including the effect of food on absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006702/),h,4.36,263210,DB05812,Abiraterone
,26006702,plasma t1/2,Onapristone plasma t1/2 (mean ± SD) was 4.36 ± 0.81 h for the fasted state and 3.76 ± 0.36 h for the fed state.,A single-dose PK study of onapristone including the effect of food on absorption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006702/),h,3.76,263211,DB05812,Abiraterone
,26006702,tmax,"Following food, onapristone tmax was delayed from 1 to 4 h.",A single-dose PK study of onapristone including the effect of food on absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006702/),h,1,263212,DB05812,Abiraterone
,26006702,tmax,"Following food, onapristone tmax was delayed from 1 to 4 h.",A single-dose PK study of onapristone including the effect of food on absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006702/),h,4,263213,DB05812,Abiraterone
,22526411,maximum plasma concentrations,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[ng] / [ml],26 to 112,269176,DB05812,Abiraterone
,22526411,maximum plasma concentrations,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[ng] / [ml],40 to 125,269177,DB05812,Abiraterone
,22526411,area under the plasma concentration-time curve from 0 to the last measurable plasma concentration,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[h·ng] / [ml],155 to 610,269178,DB05812,Abiraterone
,22526411,area under the plasma concentration-time curve from 0 to the last measurable plasma concentration,"Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study.","Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22526411/),[h·ng] / [ml],195 to 607,269179,DB05812,Abiraterone
